{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/post-traumatic-stress-disorder/prescribing-information/ssris/","result":{"pageContext":{"chapter":{"id":"8c49cc16-aec3-5fe6-98f3-6facc85e65a4","slug":"ssris","fullItemName":"SSRIs","depth":2,"htmlHeader":"<!-- begin field e42c9612-e8ed-4c24-ad7c-a9e800d4734e --><h2>SSRIs</h2><!-- end field e42c9612-e8ed-4c24-ad7c-a9e800d4734e -->","summary":"","htmlStringContent":"<!-- begin item 2019809e-c382-4291-85f2-a9e800d472e2 --><!-- end item 2019809e-c382-4291-85f2-a9e800d472e2 -->","topic":{"id":"533afaeb-861a-55f6-ae85-a0876ad3c4ab","topicId":"4676b2a0-1d7e-49c9-a79f-d2d558307370","topicName":"Post-traumatic stress disorder","slug":"post-traumatic-stress-disorder","lastRevised":"Last revised in October 2020","chapters":[{"id":"6114e299-9845-5fc0-92b9-5c972e9c90f1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"52893b93-e424-59ff-84a1-7dd9d9c8621a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4be53e3f-4d5e-556c-a6ed-aeebfd10913f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5d1733e3-23d7-5fe8-b3cd-8444b4097187","slug":"changes","fullItemName":"Changes"},{"id":"3b6b3dc7-0b46-5df1-a1c8-9e7d1cfc1bf5","slug":"update","fullItemName":"Update"}]},{"id":"924b02ab-fe04-5ca6-bfe4-efb3fa6b1e5c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ddf247aa-bfb1-5234-9e83-9df355d28fbb","slug":"goals","fullItemName":"Goals"},{"id":"afdc351f-4815-5456-9d22-1e17d70923b9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fa4ae569-9575-57de-8a77-f97e6acf134e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"441dbc06-ae69-5d87-b878-08acf874b06d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"380572c6-6c66-5ecd-bb4a-907f070efec7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"6e104865-1bd8-5bbc-a881-5acad7b59200","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f7a4b151-95d9-5da2-8bbb-3515fae24bcc","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e8e51f81-8392-5390-8f30-d6a8e5f38014","slug":"definition","fullItemName":"Definition"},{"id":"0826975d-685e-520a-9295-f3528d50f411","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"f35f4ff7-1d48-5dc1-acb1-c6b04aee33a8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c03bd4a-5a08-5bb7-8f67-78a04deaff9a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"406fb31f-fa1e-5214-b69e-e347e6875458","slug":"complications","fullItemName":"Complications"}]},{"id":"331796fb-0b83-5add-8e42-d0b72a892df8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"2ee24530-3791-5949-93f2-a856c919f68d","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"fae5c916-6c3e-5d0f-8700-e051eb95a992","fullItemName":"Management","slug":"management","subChapters":[{"id":"3a0b4bd2-81cd-5c2c-bb02-7c2734e8ebed","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2022c3bf-f856-5c11-b2fa-f455afe14e13","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8c49cc16-aec3-5fe6-98f3-6facc85e65a4","slug":"ssris","fullItemName":"SSRIs"},{"id":"21362ceb-fea6-5f5e-a2fe-3a66b96f23bb","slug":"venlafaxine","fullItemName":"Venlafaxine"}]},{"id":"ace3b310-05bb-5555-9074-19f51f5bcc46","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"94089c18-8f8a-5c71-b9fa-98bab016d27c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fb1c0b33-ff77-5312-9d64-544591ee5a16","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ab823271-5683-5fa8-9990-359b8361a067","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4977229b-c104-593f-9254-5b46fd4cef6b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"aa78f3e8-f7e9-5ec9-98a7-ab3a2ded7822","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"40d90bf9-fb45-51a8-8085-ff7f6501f6e7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ad5c3e2a-1074-579a-82d5-e2675befc03f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2022c3bf-f856-5c11-b2fa-f455afe14e13","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"918d0c89-63fd-5d69-a165-374c8b7eef98","slug":"choice-of-ssri","fullItemName":"Choice of SSRI","depth":3,"htmlHeader":"<!-- begin field cb77423a-1082-4ff8-8869-a9e801315174 --><h3>Choice of SSRI</h3><!-- end field cb77423a-1082-4ff8-8869-a9e801315174 -->","summary":"","htmlStringContent":"<!-- begin item 064a0b2c-45fa-4441-ac5b-a9e801315132 --><!-- begin field 2bf4bec6-8092-4004-89b0-a9e801315174 --><p><strong>Note: Only paroxetine and sertraline are licensed in the UK for the treatment of post-traumatic stress disorder (PTSD). Use of other SSRIs for this indication, therefore, constitutes off-licence use. </strong></p><ul><li>NICE states that there is no evidence for significant differential efficacy of specific SSRIs in the treatment of PTSD, so prescribers can decide which SSRI to use. However, they noted that of the two drugs licensed for this indication, paroxetine, is more likely to be associated with discontinuation symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">NICE, 2018</a>].</li><li>The NICE guideline <em>Depression in adults</em> recommends that the choice of drug treatment can be based on factors including the person's preference, the drug's adverse effect profile, the risk of toxicity in overdose, the possibility of interaction with any other drug treatments, and any previous response/tolerance (or otherwise) to treatment (if applicable) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">NICE, 2016</a>].</li></ul><!-- end field 2bf4bec6-8092-4004-89b0-a9e801315174 --><!-- end item 064a0b2c-45fa-4441-ac5b-a9e801315132 -->","subChapters":[]},{"id":"f42e9851-340a-5cec-b616-ce469ed1b430","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field db540564-ae5a-4a47-a614-a9e800d494cd --><h3>Contraindications and cautions</h3><!-- end field db540564-ae5a-4a47-a614-a9e800d494cd -->","summary":"","htmlStringContent":"<!-- begin item 0f7be96c-324d-4405-8dfc-a9e800d49484 --><!-- begin field 5c2d85a5-b49e-4def-bee6-a9e800d494cd --><ul><li><strong>Do not prescribe SSRIs</strong> <strong>to people:</strong><ul><li>In a manic phase of bipolar disorder.</li><li>Taking monoamine oxidase inhibitors (MAOIs), or who have recently discontinued a MAOI.</li><li>Taking pimozide.</li><li>With uncontrolled epilepsy or new onset seizures.</li></ul></li><li><strong>Do not prescribe citalopram/escitalopram to people with:</strong><ul><li>Known QT interval prolongation, or taking medication known to prolong the QT interval.</li><li>Congenital long QT syndrome.</li></ul></li><li><strong>Do not prescribe fluoxetine to people taking metoprolol to treat heart failure.</strong></li><li><strong>Prescribe SSRIs with caution</strong> <strong>to people with:</strong><ul><li>Cardiac disease</li><li>Epilepsy (discontinue if convulsions develop).</li><li>A history of bleeding disorders, especially gastrointestinal bleeding.<ul><li>Older people or people taking drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, NSAIDS or aspirin) may also be at risk. Consider prescribing a gastroprotective drug in these circumstances.</li></ul></li><li>Diabetes mellitus.</li><li>History of mania.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Also prescribe with caution to those undergoing concurrent electroconvulsive therapy.</li></ul></li><li><strong>Prescribe citalopram/escitalopram with caution</strong> <strong>to people at a higher risk than average of developing Torsade de Pointes. This includes people with:</strong><ul><li>Congestive heart failure.</li><li>Recent myocardial infarction.</li><li>Bradyarrhythmias.</li><li>Concomitant illness or medication causing a predisposition to hypokalemia or hypomagnesaemia.</li></ul></li><li><strong>Prescribe fluoxetine and sertraline with caution to people with risk factors for QTc prolongation.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>]</p><!-- end field 5c2d85a5-b49e-4def-bee6-a9e800d494cd --><!-- end item 0f7be96c-324d-4405-8dfc-a9e800d49484 -->","subChapters":[]},{"id":"cdbefe9a-1eba-5a6d-8275-e06127f4a6cf","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field af5263b4-1b69-4807-ba13-a9e800d4af4b --><h3>Adverse effects</h3><!-- end field af5263b4-1b69-4807-ba13-a9e800d4af4b -->","summary":"","htmlStringContent":"<!-- begin item 7855395e-9091-4d92-ba8a-a9e800d4af00 --><!-- begin field 968ad870-4617-48e3-add0-a9e800d4af4b --><ul><li><strong>The most common adverse effects associated with use of an SSRI are:</strong><ul><li><strong>Gastrointestinal effects </strong>— these are dose-related and include nausea, vomiting, abdominal pain, dyspepsia, constipation, and diarrhoea.</li><li><strong>Central nervous system effects</strong> — including dizziness, agitation, anxiety, insomnia, headache, and tremor.</li><li><strong>Drowsiness </strong>— may impair performance of skilled tasks such as driving and operating machinery.<ul><li>Advise the person that it is illegal in England and Wales to drive while taking a prescribed drug if it impairs driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">DVLA, 2015</a>].</li></ul></li><li><strong>Sexual dysfunction </strong>— this is also a common symptom of generalized anxiety disorder.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li><strong>Increased risk of bleeding,</strong> especially in older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example nonsteroidal anti-inflammatory drugs [NSAIDs]).</li><li><strong>Increased risk of fractures </strong>— the Medicines and Healthcare products Regulatory Agency (MHRA) has advised that SSRIs are associated with a small increased risk of fractures; however, the mechanism leading to this is unclear and may be multifactorial. </li><li><strong>Hyponatraemia </strong>— risk factors for developing hyponatraemia include a history of hyponatraemia, extreme old age (greater than 80 years of age), female sex, low body weight, diuretics, diabetes mellitus, hypertension, reduced renal function, volume depletion, and chronic obstructive pulmonary disease.<ul><li>Monitor the person for signs and symptoms of hyponatraemia (such as dizziness, lethargy, nausea, confusion, cramps, and seizures).</li></ul></li><li><strong>Increased suicide risk</strong> — this is most likely in younger people (less than 30 years of age) when starting an SSRI.<ul><li>Monitor people carefully during the first few weeks of SSRI treatment; in particular, be alert for signs of suicidal ideation, akathisia, and increased anxiety and agitation. For more information on monitoring suicide risk, see the depression topic and the section <a class=\"topic-reference external-reference\" href=\"/topics/depression/management/new-or-initial-management/#assessing-risk-of-suicide\">How do I assess the risk of suicide?</a>.</li></ul></li><li><strong>Discontinuation symptoms</strong> (such as dizziness, sensory disturbances [including paraesthesia], sleep disturbances [including insomnia and intense dreams], agitation or anxiety, nausea and/or vomiting, tremor, and headache).<ul><li>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. </li><li>Generally these symptoms are mild to moderate; however in some people they may be severe.</li><li>They usually occur within the first few days of discontinuing treatment.</li><li>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2 – 3 months or more).</li><li>It is therefore advised that an SSRI should be gradually tapered over a period of several weeks or months, according to the person's needs.</li><li>Paroxetine is associated with a higher incidence of discontinuation symptoms compared with other selective serotonin reuptake inhibitors.</li></ul></li><li><strong>For citalopram and escitalopram,</strong> <strong>QT prolongation and/or ventricular arrhythmias</strong>; especially in women, people with hypokalaemia, or people with pre-existing QT prolongation or other cardiac disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>]</p><!-- end field 968ad870-4617-48e3-add0-a9e800d4af4b --><!-- end item 7855395e-9091-4d92-ba8a-a9e800d4af00 -->","subChapters":[]},{"id":"758bf923-3d09-51a8-bb13-b482a0abfe4f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6c3f995d-8fdb-4d91-819d-a9e800d4a395 --><h3>Drug interactions</h3><!-- end field 6c3f995d-8fdb-4d91-819d-a9e800d4a395 -->","summary":"","htmlStringContent":"<!-- begin item a9f10285-e427-4424-984c-a9e800d4a357 --><!-- begin field 2998338f-d591-4aee-8b56-a9e800d4a395 --><p><strong>Key drug interactions with SSRIs as a class include:</strong></p><ul><li>5HT<sub>3</sub>- receptor agonists/antagonists (such as dapoxetine, duloxetine, fenfluramine, fentanyl, triptans, St John's Wort, tramadol, tryptophan) — possible increased serotonergic effects including serotonin syndrome.<ul><li>The manufacturer of dapoxetine advises SSRIs should not be started until 1 week after stopping dapoxetine, and to avoid dapoxetine for 2 weeks after stopping SSRIs.</li></ul></li><li>Antiepileptics — SSRIs antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered).</li><li>Aspirin, dabigatran, and NSAIDs — increased risk of bleeding.</li><li>Coumarins — SSRIs possibly enhance anticoagulant effect of coumarins.<ul><li>Consider frequent monitoring of the INR. Any change in the person's clinical condition, particularly liver disease, intercurrent illness, or drug administration, necessitates more frequent monitoring of the INR. </li></ul></li><li>Cyproheptadine — antidepressant effect of SSRIs possibly antagonised by cyproheptadine.</li><li>Drugs that can cause hyponatremia (e.g. diuretics, desmopressin, carbamazepine and oxcarbazepine) — exercise caution when prescribing concurrently as the combination may further increase the risk.</li><li>Lithium — increased risk of CNS effects when SSRIs given with lithium (lithium toxicity reported).<ul><li>Advise the person be alert for symptoms such as decreased appetite, diarrhoea, vomiting, ataxia, nystagmus, dysarthria, confusion, and seizures. Consider frequent monitoring of lithium levels.</li></ul></li><li>MAOIs — CNS effects of SSRIs increased by MAOIs (risk of serious toxicity).</li><li>Methylphenidate — metabolism of SSRIs possibly inhibited.</li><li>Pimozide — SSRIs possibly increase plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use).</li><li>Rasagiline — increased risk of CNS toxicity.</li><li>Ritonavir — plasma concentration of SSRIs possibly increased.</li><li>Tricyclic antidepressants — SSRIs increase plasma concentration of some tricyclics</li><li>Vortioxetine — possible increased risk of convulsions.</li></ul><p><strong>Key drug interactions with specific SSRIs include:</strong></p><ul><li><strong>Citalopram, escitalopram: </strong>Drugs that prolong the QT interval (including some antiarrhythmics (such as amiodarone), antipsychotics (such as haloperidol), antihistamines (such as mizolastine), and antiretrovirals (such as ritonavir, saquinavir, and lopinavir). Do not prescribe concurrently due to the potential for additive effects. Fluconazole and citalopram-  the manufacturer advises that concomitant use should only be undertaken when necessary and with caution.  </li><li><strong>Fluoxetine:</strong><ul><li>Metoprolol used for heart failure — do not prescribe concurrently. </li><li>Tamoxifen — avoid concurrent use. Fluoxetine is a potent inhibitor of the liver enzyme CYP2D6 and may reduce the plasma concentration of tamoxifen, leading to reduced efficacy.</li><li>Mequizatine — do not prescribe concurrently. The risk of mequitazine adverse events (such as QT prolongation) may be increased because of inhibition of its metabolism by fluoxetine.</li><li>Drugs that prolong the QT interval — prescribe with caution as an additive effect cannot be excluded.</li><li>Phenytoin — prescribe concurrently with caution. Changes in phenytoin blood levels and in some cases, toxicity have been observed. Consider using conservative titration schedules and monitoring clinical status.</li></ul></li><li><strong>Paroxetine:</strong><ul><li>Thioridazine — do not prescribe concurrently as this can lead to elevated plasma levels of thioridazine, increasing the risk of QTc interval prolongation with associated serious ventricular arrhythmia such as torsades de pointes, and sudden death.</li><li>Tamoxifen — avoid concurrent use. Paroxetine is a potent inhibitor of the liver enzyme CYP2D6 and may reduce the plasma concentration of tamoxifen, leading to reduced efficacy.</li><li>Aripiprazole, clozapine, darifenacin, galantamine, methadone, metoprolol, pitolisant, procyclidine, ranolazine, risperidone and vortioxetine — exercise caution as paroxetine may increase the plasma concentrations of these drugs.</li><li>Atomoxetine, perphenazine, and propafenone — exercise caution as paroxetine may inhibit the metabolism of these drugs.</li><li>Asenapine, darunavir, fosphenytoin, phenobarbital, phenytoin, primidone, ritonavir, and terbinafine — exercise caution as plasma concentration of paroxetine may be altered by these drugs.</li></ul></li><li><strong>Sertraline: </strong>Drugs that prolong the QT interval — exercise caution when using concurrently as the risk of QTc prolongation and/or ventricular arrhythmias may be increased.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2020a</a>]</p><!-- end field 2998338f-d591-4aee-8b56-a9e800d4a395 --><!-- end item a9f10285-e427-4424-984c-a9e800d4a357 -->","subChapters":[]},{"id":"f786d709-8a1a-5ec9-a144-bbf4f3618a14","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field 3df8a409-bb44-41dc-96d4-a9e800d4b8ef --><h3>Dosage</h3><!-- end field 3df8a409-bb44-41dc-96d4-a9e800d4b8ef -->","summary":"","htmlStringContent":"<!-- begin item 629fd1d5-1003-47da-8afd-a9e800d4b899 --><!-- begin field 98391af1-462b-4177-a97a-a9e800d4b8ef --><p><strong>Note: Only paroxetine and sertraline are licensed in the UK for the treatment of post-traumatic stress disorder (PTSD). Use of other SSRIs for this indication therefore constitutes off-licence use. </strong></p><ul><li><strong>For citalopram:</strong> prescribe a starting dose of 10 mg daily, increased gradually in steps of 10 mg if required, usual dose 20–30 mg daily; maximum 40 mg per day.<ul><li>Note: as citalopram is not licensed for use in PTSD, the recommended doses are licensed doses for panic disorder.</li></ul></li><li><strong>For escitalopram:</strong> prescribe a starting dose of 10 mg once daily. Dose may be increased to a maximum of 20 mg a day (except in elderly people and those with reduced hepatic function).<ul><li>Note: as escitalopram is not licensed for use in PTSD, the recommended doses are licensed doses for generalized anxiety disorder.</li></ul></li><li><strong>For fluoxetine:</strong> prescribe a starting dose of 20 mg daily. Increase gradually to a maximum of 60 mg daily if required. Consider the long half-life of fluoxetine when adjusting dosage.<ul><li>Note: as fluoxetine is not licensed for use in PTSD, the recommended doses are licensed doses for major depression and obsessive-compulsive disorder.</li></ul></li><li><strong>For paroxetine: </strong>prescribe a starting dose of 20 mg a day to be taken in the morning. The maximum licensed dose for the treatment of PTSD is 50 mg/day in adults with 40 mg/day recommended in the elderly.</li><li><strong>For sertraline: </strong>prescribe a starting dose of 25 mg daily for one week, then increase to 50 mg daily. Dose may be further increased if required/tolerated in steps of 50 mg, at intervals of at least one week. The maximum licensed dose for the treatment of PTSD is 200 mg a day.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>]</p><!-- end field 98391af1-462b-4177-a97a-a9e800d4b8ef --><!-- end item 629fd1d5-1003-47da-8afd-a9e800d4b899 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}